Stockreport

Q32 Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]

Q32 Bio Inc.  (QTTB) 
PDF -- Enrollment ongoing in ADX-097 Phase 2 basket trial for complement mediated renal diseases, with topline data expected in 2H'25 and initial open-label data in 1H'25 - [Read more]